Postnatal intravenous steroids and long-term neurological outcome: Recommendations from meta-analyses

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 97, Issue 4, 2012, Pages

  Yates, H L ^a   Newell, S J ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; STEROID;

CEREBRAL PALSY; CHRONIC LUNG DISEASE; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG DOSE REGIMEN; EXTUBATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; META ANALYSIS (TOPIC); METABOLIC DISORDER; NERVOUS SYSTEM DEVELOPMENT; NEWBORN DISEASE; NEWBORN MORTALITY; POSTNATAL CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK REDUCTION; STEROID THERAPY; SYSTEMATIC REVIEW (TOPIC);

CEREBRAL PALSY; CHRONIC DISEASE; DEVELOPMENTAL DISABILITIES; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INJECTIONS, INTRAVENOUS; LUNG DISEASES; PROGNOSIS;

EID: 84863450490     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2010.208868     Document Type: Review

References (29)

1. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;1:CD001146.
2. Halliday HL, Ehrenkanz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;1:CD001144.
3. Halliday HL, Ehrenkanz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003;1:CD001145.
4. Halliday HL, Ehrenkranz RA, Doyle LW. Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009;1:CD001146.
5. Halliday HL, Ehrenkanz RA, Doyle LW. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009;1:CD001145.
6. Walsh MC, Yao Q, Horbar JD, et al. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 2006;118:e1328-35. (Pubitemid 46393637)
7. Shinwell ES, Lerner-Geva L, Lusky A, et al. Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed 2007;92:F30-3. (Pubitemid 46132963)
8. Wilson-Costello D, Friedman H, Minich N, et al. Improved neurodevelopmental outcomes for extremely low birth weight infants in 2000-2002. Pediatrics 2007;119:37-45. (Pubitemid 46397840)
9. Wood NS, Costeloe K, Gibson AT, et al. The EPICure study: associations and antecedents of neurological and developmental disability at 30 months of age following extremely preterm birth. Arch Dis Child Fetal Neonatal Ed 2005;90:F134-40. (Pubitemid 40333082)
10. Fitzhardinge PM, Eisen A, Lejtenyi C, et al. Sequelae of early steroid administration to the newborn infant. Pediatrics 1974;53:877-83.
11. Baden M, Bauer CR, Colle E, et al. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics 1972;50:526-34.
12. Shinwell ES, Karplus M, Reich D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000;83:F177-81.
13. O'Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999;104:15-21. (Pubitemid 29315841)
14. Jones R, Wincott E, Elbourne D, et al. Controlled trial of dexamethasone in neonatal chronic lung disease: a 3-year follow-up. Pediatrics 1995;96:897-906.
15. Yeh TF, Lin YJ, Huang CC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 1998;101:E7.
16. Subhedar NV, Bennett AJ, Wardle SP, et al. More trials on early treatment with corticosteroids are needed. BMJ 2000;320:941. (Pubitemid 30182400)
17. Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 1989;320:1505-10. (Pubitemid 19145801)
18. Vincer MJ, Allen AC. Double blind controlled trial of a 6-day pulse of dexamethasone for very low birth weight infants (VLBW< 1500g) who are ventilator dependent at 4 weeks of age. Ped Res 1998;43:201.
19. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr 2001;1:1.
20. American Academy of Paediatrics Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002;109:300-38.
21. Canadian Paediatric Society. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Paediatr Child Health 2002;7:20-8.
22. Halliday HL. Guidelines on neonatal steroids. Prenat Neonat Med 2001;6:371-3. (Pubitemid 34098397)
23. Yoder BA, Harrison M, Clark RH. Time-related changes in steroid use and bronchopulmonary dysplasia in preterm infants. Pediatrics 2009;124:673-9.
24. Kaempf JW, Campbell B, Sklar RS, et al. Implementing potentially better practices to improve neonatal outcomes after reducing postnatal dexamethasone use in infants born between 501 and 1250 grams. Pediatrics 2003;111:e534-41.
25. Niwas R, Kamat M, Kling P, et al. Postnatal corticosteroids to treat or to prevent chronic lung disease: a survey of neonatologists' practices. Arch Dis Child Fetal Neonatal Ed 2009;94:F77.
26. Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 2005;115:655-61. (Pubitemid 43373025)
27. Onland W, De Jaegere AP, Offringa M, et al. Effects of higher versus lower dexamethasone doses on pulmonary and neurodevelopmental sequelae in preterm infants at risk for chronic lung disease: a meta-analysis. Pediatrics 2008;122:92-101.
28. Onland W, Offringa M, De Jaegere AP, et al. Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials. Pediatrics 2009;123:367-77.
29. Wilson-Costello D, Walsh MC, Langer JC, et al. Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants. Pediatrics 2009;123:e430-7.